GSK1904529A, which potently inhibits IGF-IR (IC50= 27 nmol/L) and IR (IC50= 25 nmol/L) activities in vitro and in vivo, is a promising candidate for therapeutic use in solid and hematologic cancers.
ChemScene can order timely high quality and efficient services of various compounds from mg to kg level for some clients' bioscience research. We are committed to researching and developing reference compounds with high synthesis technology barriers and difficulties. ChemScene also has a tradition of working with scientists to bring new discoveries out of the laboratory and into the commercial arena.
View more >>